370 related articles for article (PubMed ID: 32928237)
1. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Yeku O; Russo AL; Lee H; Spriggs D
J Transl Med; 2020 Sep; 18(1):350. PubMed ID: 32928237
[TBL] [Abstract][Full Text] [Related]
2. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma.
Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T
BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286
[TBL] [Abstract][Full Text] [Related]
3. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
4. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
5. Prolonged continuous infusion cisplatin and 5-fluorouracil with radiation for locally advanced carcinoma of the vulva.
Eifel PJ; Morris M; Burke TW; Levenback C; Gershenson DM
Gynecol Oncol; 1995 Oct; 59(1):51-6. PubMed ID: 7557615
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
8. Association of Radiochemotherapy to Immunotherapy in unresectable locally advanced Oesophageal carciNoma-randomized phase 2 trial ARION UCGI 33/PRODIGE 67: the study protocol.
Modesto A; Tougeron D; Tremolières P; Ronchin P; Jouve AD; Leignel DA; Vendrely V; Riou O; Martin-Babau J; Le Sourd S; Mirabel X; Leroy T; Huguet F; Montaigne L; Baumgaertner I; Deslandres M; Moyal E; Seva C; Selves J; Otal P; Pezzella V; Guimbaud R; Filleron T; Quéro L
BMC Cancer; 2023 Oct; 23(1):966. PubMed ID: 37828434
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial.
How JA; Jazaeri AA; Soliman PT; Fleming ND; Gong J; Piha-Paul SA; Janku F; Stephen B; Naing A
Sci Rep; 2021 Feb; 11(1):3667. PubMed ID: 33574401
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
12. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001).
Shang X; Zhao G; Liang F; Zhang C; Zhang W; Liu L; Li R; Duan X; Ma Z; Yue J; Chen C; Meng B; Ren X; Jiang H
Ann Transl Med; 2022 Feb; 10(4):229. PubMed ID: 35280363
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
Hahn AW; Chahoud J; Campbell MT; Karp DD; Wang J; Stephen B; Tu SM; Pettaway CA; Naing A
Invest New Drugs; 2021 Oct; 39(5):1405-1410. PubMed ID: 33770291
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Weickhardt A; Foroudi F; Lawrentschuk N; Xie J; Sidhom M; Pal A; Grimison P; Zhang A; Ng S; Tang C; Hovey E; Chen C; Hruby G; Guminski A; McJannett M; Conduit C; Tran B; Davis ID; Hayne D
Eur Urol Oncol; 2024 Jun; 7(3):469-477. PubMed ID: 37806844
[TBL] [Abstract][Full Text] [Related]
18. Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
Levy B; Paz-Ares L; Bennouna J; Felip E; Abreu DR; Isla D; Barlesi F; Molinier O; Madelaine J; Audigier-Valette C; Kim SW; Kim HR; Ozguroglu M; Erman M; Badin FB; Mekhail TM; Scheff R; Chisamore MJ; Sadrolhefazi B; Riess JW
Clin Lung Cancer; 2019 May; 20(3):e407-e412. PubMed ID: 30808583
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT).
Schmid SC; Koll FJ; Rödel C; Maisch P; Sauter A; Beckert F; Seitz A; Kübler H; Flentje M; Chun F; Combs SE; Schiller K; Gschwend JE; Retz M
BMC Cancer; 2020 Jan; 20(1):8. PubMed ID: 31900121
[TBL] [Abstract][Full Text] [Related]
20. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
Long GV; Dummer R; Hamid O; Gajewski TF; Caglevic C; Dalle S; Arance A; Carlino MS; Grob JJ; Kim TM; Demidov L; Robert C; Larkin J; Anderson JR; Maleski J; Jones M; Diede SJ; Mitchell TC
Lancet Oncol; 2019 Aug; 20(8):1083-1097. PubMed ID: 31221619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
